药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Isoprenaline
Dacomitinib
Cholesterol may increase the excretion rate of Dacomitinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Duvelisib
Cholesterol may increase the excretion rate of Duvelisib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Revefenacin
Cholesterol may increase the excretion rate of Revefenacin which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Ertugliflozin
Cholesterol may increase the excretion rate of Ertugliflozin which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Talazoparib
Cholesterol may increase the excretion rate of Talazoparib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Velpatasvir
Cholesterol may increase the excretion rate of Velpatasvir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Venetoclax
Cholesterol may increase the excretion rate of Venetoclax which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Osimertinib
Cholesterol may increase the excretion rate of Osimertinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Tenofovir alafenamide
Cholesterol may increase the excretion rate of Tenofovir alafenamide which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Ombitasvir
Cholesterol may increase the excretion rate of Ombitasvir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Lenvatinib
Cholesterol may increase the excretion rate of Lenvatinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Palbociclib
Cholesterol may increase the excretion rate of Palbociclib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Idelalisib
Cholesterol may increase the excretion rate of Idelalisib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Sofosbuvir
Cholesterol may increase the excretion rate of Sofosbuvir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Dolutegravir
Cholesterol may increase the excretion rate of Dolutegravir which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Afatinib
Cholesterol may increase the excretion rate of Afatinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Dabrafenib
Cholesterol may increase the excretion rate of Dabrafenib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Ponatinib
Cholesterol may increase the excretion rate of Ponatinib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Vemurafenib
Cholesterol may increase the excretion rate of Vemurafenib which could result in a lower serum level and potentially a reduction in efficacy.
Isoprenaline
Pitavastatin
Cholesterol may increase the excretion rate of Pitavastatin which could result in a lower serum level and potentially a reduction in efficacy.